Experimental combo therapy aims to outsmart lymphoma
NCT ID NCT05801913
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It combines specially engineered immune cells (CAR T cells) that target cancer cells with a vaccine designed to boost the immune response. The main goals are to see if the combination is safe and feasible to produce and deliver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CMV-specific CD19-CAR T cells and CMV-MVA triplex vaccine
What this could lead to
If successful, this approach could offer a new treatment option for patients with hard-to-treat B-cell non-Hodgkin lymphoma that has returned or not responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 15 participants, so it is primarily testing safety and feasibility. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome and neurotoxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact